CL2020002347A1 - Nuevo compuesto y composición farmacéutica que lo comprende - Google Patents

Nuevo compuesto y composición farmacéutica que lo comprende

Info

Publication number
CL2020002347A1
CL2020002347A1 CL2020002347A CL2020002347A CL2020002347A1 CL 2020002347 A1 CL2020002347 A1 CL 2020002347A1 CL 2020002347 A CL2020002347 A CL 2020002347A CL 2020002347 A CL2020002347 A CL 2020002347A CL 2020002347 A1 CL2020002347 A1 CL 2020002347A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
new compound
present disclosure
autophagy
compound
Prior art date
Application number
CL2020002347A
Other languages
English (en)
Inventor
Jung Ju Kim
Seong-Won Song
Hye Jeong Shin
Hyeongwan Choi
Original Assignee
Autophagysciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autophagysciences Inc filed Critical Autophagysciences Inc
Publication of CL2020002347A1 publication Critical patent/CL2020002347A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/08—Hydrogen atoms or radicals containing only hydrogen and carbon atoms
    • C07D333/10—Thiophene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente divulgación se refiere a un compuesto novedoso y a una composición farmacéutica que comprende el mismo. El compuesto según la presente divulgación tiene efectos para activar la autofagia y, por tanto, puede usarse de manera útil para prevenir o tratar enfermedades asociadas con la regulación de la autofagia.
CL2020002347A 2018-06-01 2020-09-10 Nuevo compuesto y composición farmacéutica que lo comprende CL2020002347A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20180063496 2018-06-01

Publications (1)

Publication Number Publication Date
CL2020002347A1 true CL2020002347A1 (es) 2021-01-15

Family

ID=68698300

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002347A CL2020002347A1 (es) 2018-06-01 2020-09-10 Nuevo compuesto y composición farmacéutica que lo comprende

Country Status (13)

Country Link
US (1) US11407744B2 (es)
EP (1) EP3805210B1 (es)
JP (1) JP7177577B2 (es)
KR (1) KR102308713B1 (es)
CN (1) CN112004807B (es)
AU (1) AU2019279441B2 (es)
BR (1) BR112020022220A2 (es)
CA (1) CA3100308C (es)
CL (1) CL2020002347A1 (es)
ES (1) ES2971118T3 (es)
IL (1) IL276783B2 (es)
MX (1) MX2020009287A (es)
WO (1) WO2019231290A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112437773B (zh) * 2018-07-20 2024-06-11 六合医药科技有限公司 新的儿茶酚衍生物或其盐，其制备方法以及包含其的药物组合物
CN113929591A (zh) * 2021-10-09 2022-01-14 中国科学技术大学 具有抗增殖活性的抑制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1626713A2 (en) * 2003-05-16 2006-02-22 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
EP1708697A4 (en) * 2004-01-30 2007-11-28 Smithkline Beecham Corp CHEMICAL COMPOUNDS
TWI423962B (zh) 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
WO2012085170A2 (en) 2010-12-22 2012-06-28 Haag Benjamin Process for making organoboron compounds, products obtainable thereby, and their use
KR101721490B1 (ko) * 2014-07-30 2017-03-30 한국생명공학연구원 페닐 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 세포증식성 질병의 예방 또는 치료용 약학적 조성물
KR102100470B1 (ko) * 2015-08-21 2020-04-13 (주)오토파지사이언스 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물

Also Published As

Publication number Publication date
IL276783B2 (en) 2023-12-01
JP7177577B2 (ja) 2022-11-24
KR20190137711A (ko) 2019-12-11
BR112020022220A2 (pt) 2021-02-02
EP3805210A1 (en) 2021-04-14
KR102308713B1 (ko) 2021-10-05
EP3805210A4 (en) 2022-01-19
MX2020009287A (es) 2020-09-28
IL276783A (en) 2020-10-29
CA3100308C (en) 2024-02-20
WO2019231290A1 (ko) 2019-12-05
IL276783B1 (en) 2023-08-01
CA3100308A1 (en) 2019-12-05
CN112004807A (zh) 2020-11-27
US20210078987A1 (en) 2021-03-18
AU2019279441A1 (en) 2020-08-27
ES2971118T3 (es) 2024-06-03
CN112004807B (zh) 2023-07-18
AU2019279441B2 (en) 2024-02-29
US11407744B2 (en) 2022-08-09
JP2021534072A (ja) 2021-12-09
EP3805210B1 (en) 2023-11-29

Similar Documents

Publication Publication Date Title
CL2020002032A1 (es) Cristal de un compuesto derivado de 7,8-difluoro-6,11-dihidrodibenzotiepina, composición farmacéutica, útil en reducir el tiempo de alivio de los síntomas de la influenza para tratar y/o prevenir una infección provocada por el virus de la influenza. (divisional solicitud 201900325).
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
MX2020009455A (es) Composiciones que comprenden cepas bacterianas.
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
CL2016002971A1 (es) Combinación.
BR112016028255A2 (pt) agentes imunorreguladores
MX2018000412A (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
MX2016009625A (es) Proteinas quimericas tipo fosfatasa alcalina.
MX2021003170A (es) Moduladores de la expresion de pnpla3.
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
CR20190471A (es) Moduladores de la expresión de pcsk9
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.
MX2020003947A (es) Anticuerpo anti-cd3 y composicion farmaceutica para el tratamiento del cancer que comprende el mismo.
MX2019010950A (es) Composicion de fotosensibilizador que contiene fenalen-1-ona, compuesto de fenalen-1-ona, asi como su uso.
DOP2020000077A (es) Nuevo derivado de fenilpiridina y composición farmacéutica que lo contiene
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
HK1257296A1 (zh) 新的化合物及其用途
CO2021001849A2 (es) Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende
MX2020003943A (es) Anticuerpo anti-msln y composicion farmaceutica para el tratamiento del cancer que comprende el mismo.
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
CL2020002347A1 (es) Nuevo compuesto y composición farmacéutica que lo comprende
CL2019001618A1 (es) Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.